Envista Holdings Co. (NYSE:NVST) Receives Consensus Rating of “Hold” from Analysts

Envista Holdings Co. (NYSE:NVST) has received an average recommendation of “Hold” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $20.13.

A number of equities research analysts have recently issued reports on NVST shares. Needham & Company LLC restated a “hold” rating on shares of Envista in a research report on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Envista in a research report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price objective for the company. Jefferies Financial Group boosted their target price on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Leerink Partnrs upgraded shares of Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Finally, Robert W. Baird increased their price objective on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st.

Envista Stock Up 0.8 %

NYSE NVST opened at $21.77 on Friday. Envista has a one year low of $15.15 and a one year high of $24.79. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. The business has a fifty day moving average price of $20.05 and a 200 day moving average price of $18.91. The company has a market cap of $3.75 billion, a P/E ratio of -2.80, a P/E/G ratio of 1.88 and a beta of 1.33.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm had revenue of $601.00 million for the quarter, compared to the consensus estimate of $590.34 million. During the same period last year, the firm posted $0.43 earnings per share. The company’s revenue for the quarter was down 4.8% on a year-over-year basis. Research analysts anticipate that Envista will post 0.72 EPS for the current fiscal year.

Institutional Trading of Envista

Several hedge funds have recently made changes to their positions in NVST. Empowered Funds LLC acquired a new stake in Envista during the 4th quarter worth approximately $374,000. Lecap Asset Management Ltd. purchased a new stake in shares of Envista during the fourth quarter worth $281,000. Hantz Financial Services Inc. increased its position in shares of Envista by 146.6% during the fourth quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company’s stock worth $2,131,000 after acquiring an additional 65,679 shares during the period. KBC Group NV increased its holdings in Envista by 63.9% during the 4th quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after purchasing an additional 3,082 shares during the period. Finally, Hedges Asset Management LLC boosted its stake in shares of Envista by 13.9% in the 4th quarter. Hedges Asset Management LLC now owns 53,300 shares of the company’s stock valued at $1,028,000 after buying an additional 6,500 shares during the period.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.